AC Immune Announces Results of Annual General Meeting
- Financial expert Mr. Thomas Graney elected as new member of the Board of Directors
- Shareholders approve all proposed resolutions of the board of directors
LAUSANNE, Switzerland, Nov. 15, 2016 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the company have elected Mr. Thomas Graney as a new member of the Board of Directors of the Company at its Annual General Meeting held at EPFL Innovation Park, Lausanne.
Martin Velasco, Chairman of the Board of Directors of AC Immune, commented, "We are very pleased to welcome Tom Graney to our Board of Directors, the Compensation, Nomination and Corporate Governance Committee and the Finance and Audit Committee. His experience in corporate finance and international business and development will bring great expertise and experience to our Board. This comes at the right time as we transition AC Immune into a publicly traded company and continue to develop our strong pipeline of therapeutics and diagnostics targeting neurodegenerative disorders."
The shareholders of the company also approved all other resolutions proposed. The detailed resolutions are available on the company's website. Furthermore, AC Immune confirms that Dr. Mathias Hothum has retired from the Board at the conclusion of the Annual General Meeting.
About Mr. Tom Graney Mr. Graney serves as Chief Financial Officer and Senior Vice President of Finance & Corporate Strategy at Ironwood Pharmaceuticals, Inc., a post held since September 2014. Prior to Ironwood his professional career included 20 years with Johnson & Johnson and its affiliates, serving for four years as Worldwide Vice President of Finance and Chief Financial Officer of Ethicon, a Johnson & Johnson company. In addition, Mr. Graney has extensive global experience spanning corporate development, commercial strategy, portfolio management and supply chain management. Mr. Graney is a Chartered Financial Analyst charterholder and holds a B.S. in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.
About AC Immune AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease. The Company's pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in phase 3 clinical studies that is being advanced by the collaboration partner Genentech, Inc., a wholly owned subsidiary of Roche. Other business partners include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences and Piramal Imaging.
Forward looking statements This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of AC Immune's product candidates, the clinical utility of AC Immune's product candidates, the timing or likelihood of regulatory filings and approvals, AC Immune's intellectual property position and AC Immune's financial position. These risks and uncertainties also include those described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in AC Immune's Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
For further information please contact:
| Prof. Andrea Pfeifer Chief Executive Officer Phone: +41-21-345 91 21 E-mail: andrea.pfeifer@acimmune.com | Eva Schier Corporate Communications Manager Phone: +41-21-345 91 34 Mobile: +41 79 926 66 03 E-mail: eva.schier@acimmune.com |
| Nick Miles/ Toomas Kull Cabinet Privé de Conseils s.a. Phone : +41 22 321 45 40 E-mail : miles@cpc-pr.com kull@cpc-pr.com | In the US Ted Agne The Communications Strategy Group Inc. Phone: +1 781 631 3117 E-mail: edagne@comstratgroup.com |
